Toxicity of antiretroviral therapy and implications for drug development.
Carr
Andrew
A
HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital, Sydney 2010, Australia. acarr@stvincents.com.au
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D002986:Clinical Trials as Topic / Q000379:methods*; D015195:Drug Design; D004342:Drug Hypersensitivity / Q000209:etiology / Q000503:physiopathology; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D015497:HIV-1; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced* / Q000503:physiopathology; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors